Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Art-only Clear all
Completed Phase 1Phase 2 Interventional Results available

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

NCT03497676
View directory record Official record
Conditions
HIV Infections
Interventions
Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 17 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 24, 2026, 11:46 PM EDT
Active, not recruiting Not applicable Interventional

WiseApp for Spanish Speakers Living With HIV

NCT05398185
View directory record Official record
Conditions
HIV Infections, Acquired Immune Deficiency Syndrome, Sexually Transmitted Diseases, Viral
Interventions
CleverCap
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Not applicable Interventional

MUSic Therapy to Improve Quality Of Life in Sickle Cell Disease (MUSIQOLS)

NCT03556657
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Pain
Interventions
Music Therapy
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

NCT00887653
View directory record Official record
Conditions
HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Atazanavir/Ritonavir Maintenance Therapy

NCT00084019
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Palo Alto, California • Aurora, Colorado • Honolulu, Hawaii + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

NCT00842634
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
ZFN modified T cells, Structured Treatment Interruption
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 24, 2026, 11:46 PM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

NCT01791465
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection, Diabetes Mellitus
Interventions
extended-release exenatide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

NCT06039579
View directory record Official record
Conditions
HIV Infections
Interventions
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Bakersfield, California • DeLand, Florida • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 24, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

NCT06984562
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Interventions
Adaptive Radiation Therapy
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

Menopur Mixed Protocol

NCT01417195
View directory record Official record
Conditions
Infertility
Interventions
Bravelle, Menopur
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Lone Tree, Colorado • Clearwater, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 4 Interventional

Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer

NCT02254577
View directory record Official record
Conditions
Infertility
Interventions
Endometrin® plus Progesterone in Oil (PIO), Progesterone in Oil (PIO) Only
Drug
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Observation of Perioperative Outcomes of Robotic Pancreaticoduodenectomy

NCT04171440
View directory record Official record
Conditions
Pancreaticoduodenectomy
Interventions
robotic pancreaticoduodenectomy
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 24, 2026, 11:46 PM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of SAR441236

NCT03705169
View directory record Official record
Conditions
HIV-1-infection
Interventions
SAR441236, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

The Effect of Play on Social and Motor Skills of Children With ASD

NCT04258254
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Multimodal, General, Standard of Care
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
5 Years to 15 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 24, 2026, 11:46 PM EDT
Terminated No phase listed Observational

A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment

NCT00001069
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

NCT00000825
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 24, 2026, 11:46 PM EDT
Not listed Phase 4 Interventional

Empiric Treatment for Acute HIV in the ED

NCT03711253
View directory record Official record
Conditions
Acute HIV Infection
Interventions
Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

NCT00344461
View directory record Official record
Conditions
HIV
Interventions
Nevirapine, FTC, and Tenofovir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

NCT04983030
View directory record Official record
Conditions
HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections
Interventions
Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS
Biological
Lead sponsor
Boris Juelg, MD PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Orlando, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 24, 2026, 11:46 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

NCT06252402
View directory record Official record
Conditions
HIV-1
Interventions
CMV/HIV-CAR T Cells
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 24, 2026, 11:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

CAR-T Cells for HIV Infection

NCT04648046
View directory record Official record
Conditions
HIV Infections
Interventions
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Drug · Biological · Other
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

NCT03844386
View directory record Official record
Conditions
HIV-1 Infection
Interventions
MVA.tHIVconsv3, MVA.tHIVconsv4, Placebo
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 24, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Results available

Study of Novel Antiretrovirals in Participants With HIV-1

NCT05585307
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 24, 2026, 11:46 PM EDT